US 12,329,830 B2
Composition containing a somatostatin analogue for radiopharmaceutical use
Romain Bejot, Wrexham (GB); Bilal Karaaoui, Dreux (FR); Didier Kubiak, Dreux (FR); Anne-Claire Le Meur, Dreux (FR); Didier Nourrisson, Dreux (FR); Anne Petit, Dreux (FR); Joel Richard, Dreux (FR); and Camille Toulisse, Dreux (FR)
Assigned to Ariceum Therapeutics GmbH, Berlin (DE)
Appl. No. 17/251,786
Filed by Ariceum Therapeutics GmbH, Berlin (DE)
PCT Filed Jun. 20, 2019, PCT No. PCT/EP2019/066327
§ 371(c)(1), (2) Date Dec. 12, 2020,
PCT Pub. No. WO2019/243487, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 18179054 (EP), filed on Jun. 21, 2018.
Prior Publication US 2021/0128758 A1, May 6, 2021
Int. Cl. A61K 51/08 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 51/12 (2006.01)
CPC A61K 51/083 (2013.01) [A61K 47/18 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 51/088 (2013.01); A61K 51/121 (2013.01); A61K 51/1241 (2013.01)] 21 Claims
 
1. A receptor-selective somatostatin peptide antagonist composition comprising:
a DOTA-peptide of Formula (I)

OG Complex Work Unit Chemistry
or a salt thereof,
an antioxidant, and
a bulking agent, wherein the bulking agent is arginine, and
wherein the weight ratio of the arginine over the DOTA-peptide is of from 15:1 to 45:1.